FORSTEO(R) Receives Approval From The European Commission For The Treatment Of Glucocorticoid Induced Osteoporosis (Medical News Today)
Eli Lilly and Company (NYSE: LLY) announced that the European Commission has approved a new indication for FORSTEO(R) (teriparatide [rDNA origin] injection) for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in women and men at increased risk for fracture.